Clinical Trial Update: An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update indicates Brazikumab in moderately to severely active Crohn's disease (IBD) was terminated in a combined Phase 2/Phase 3 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease

Drugs mentioned

• Brazikumab

Snippet

Sponsor: AstraZeneca | Conditions: Crohn's Disease, IBD | Phase 2, Phase 3 | Status: TERMINATED